Disease · MONDO_0021315
malignant tumor of nasopharynx
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. malignant tumor of nasopharynx. Diseases, record MONDO_0021315. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021315
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
cancer of nasopharynx, malignant nasopharyngeal neoplasm, malignant nasopharyngeal tumor, malignant nasopharyngeal tumour, malignant nasopharynx neoplasm, malignant neoplasm of nasopharynx, malignant neoplasm of the nasopharynx, malignant tumor of the nasopharynx, malignant tumour of the nasopharynx, nasopharynx cancer
- Open Targets
Drugs3
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets1
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes |
|---|---|---|---|---|---|
| TYMS | Thymidylate synthase | 1 | Thymidylate synthase inhibitor | Phase 3 | https://conductscience.org/library/genes/7298 |
Source Drugs and targets
Trials2
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01706939 | The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer | Phase 3 | 23 | 2022-09-01 | Squamous Cell Carcinomas | CARBOPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT00003637 | Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx | Phase 3 | 200 | Head and Neck Cancer | CISPLATIN, FLUOROURACIL | Open Targets' reading of its record | ClinicalTrials.gov |
Comparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Reduced Dose Radiation vs Standard Dose Radiation: Number of Participants With Acute Toxicity of Chemoradiotherapy (CRT) | 3 of 12 | 1 of 8 | 20 | NCT01706939 | Trial comparisons |
| Reduced Dose Radiation vs Standard Dose Radiation: Number of Participants With Local-regional Control | 10 of 12 | 7 of 8 | 20 | NCT01706939 | Trial comparisons |
| Reduced Dose Radiation vs Standard Dose Radiation: Number of Participants With Overall Survival at 5 Years | 10 of 12 | 7 of 8 | 20 | NCT01706939 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0021315
GET https://conductscience.org/api/diseases/v1/MONDO_0021315/drugs